# A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy

> **NCT00558675** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mirror Biologics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Hematological Malignancy
- Leukemia
- Lymphoma
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** AlloStim
- **BIOLOGICAL:** AlloStim
- **BIOLOGICAL:** AlloStim
- **BIOLOGICAL:** AlloStim

## Key facts

- **NCT ID:** NCT00558675
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2013-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558675, "A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00558675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*